Partners in Science

Thomas Tobin, MVB, MRCVS [DVM], Ph.D.
Lawrence Soma, DVM, DACVA
Michael Gliddon, Ph.D.
Frank Andrews, DVM, MS, DACVIM
N. Edward Robinson, B. Vet.Med., Ph.D.
Craig R. Reinemeyer, DVM, Ph.D.
Laurent L. Couetil, Ph.D.
Mary Robinson, VMD, Ph.D.
John Byrd, Ph.D.
Linda Gebhard – LG Consulting Services

Thomas Tobin, MVB, MRCVS [DVM], Ph.D.

Dr. Tobin is a veterinarian, a doctoral level pharmacologist, and a board certified toxicologist. For the last 27 years his professional focus has been in the area of drug and medication control, therapeutics and toxicology in performance horses. Dr. Tobin wrote the standard textbook in the area of equine medication control, Drugs and the Performance Horse, 1981, and has been invited to present his expert professional opinion worldwide. Along with Dr. David Watt and Dr. Daniel Tai, Dr. Tobin began the research program & founded the company that introduced Enzyme-Linked Immunosorbent Assay (ELISA) testing into horse racing. The introduction of this technology has revolutionized equine medication control worldwide, and led to tests that developed and brought to market many of the industry’s most widely used medications. Dr. Tobin is currently Professor of Veterinary Science at the Gluck Equine Research Center and Graduate Center for Toxicology, University of Kentucky.

Lawrence Soma, DVM, DACVA

Dr. Soma is Professor of Anesthesia and the Marilyn M. Simpson Professor of Veterinary Medicine at the University of Pennsylvania, School of Veterinary Medicine and Chairman of the University of Pennsylvania School of Veterinary Medicine’s New Bolton Center Endowed Chair Committee, as well as the Principal Investigator, Pennsylvania Racing Commission Research Program. Dr. Soma and his colleagues at the New Bolton Center and Pennsylvania Equine Toxicology and Research Lab (PETRL) developed the world’s first method for confirming doping agents in the blood of equine athletes. This method for screening, confirming and quantifying the presence of anabolic steroids in plasma, as opposed to urine, produced a testing process that is both faster and more cost effective, and is now the standard of the industry.

<< Back to top

Michael Gliddon, Ph.D.

Dr. Gliddon recently served as the Senior Director of the Animal Health Formulations Analytical and Process Development department of Fort Dodge Animal Health (now Pfizer Animal Heath), where he was responsible for the supervision, scientific leadership and budgeting of the formulations, analytical, and process development departments consisting of approximately forty professional scientists involved in the development, global registration and manufacturing support for new and existing animal health products.

Frank Andrews, DVM, MS, DACVIM

Dr. Andrews is the Director of the LSU Equine Health Studies Program at the Louisiana State University School of Veterinary Medicine. His research interests lie in equine gastroenterology, specifically gastric ulcers. He has published over 100 refereed articles and book chapters and has presented his research nationally and internationally.  In addition to his academic work, Dr. Andrews has served on numerous scientific boards and in societies such as the Equine Protozoal Myeloencephalitis Society (current president) and the Equine Advisory Council with Astra-Zeneca, Merial and Intervet, Inc.

<< Back to top

N Edward Robinson, B. Vet.Med., Ph.D.

Dr. Robinson is the Director of the Equine Pulmonary Laboratory for the College of Veterinary Medicine at Michigan State University. For the past twenty years Dr. Robinson has been investigating the pathogenesis of chronic, noninfectious airway diseases, particularly COPD in horses. He and his staff have collaborated with Boehringer, 3M and Bayer in the development and testing of products and devices for the treatment of equine airway disease. Dr. Robinson is on the editorial board of the American Journal of Veterinary Research, Equine Veterinary Education, Equine Veterinary Journal, Equus, The Horse, and Veterinary Research Communications in addition to serving on the Scientific Advisory Committee of the Animal Health Trust, Newmarket, England.

Craig R. Reinemeyer, DVM, Ph.D.

Dr. Reinemeyer left academia in 1998 to found East Tennessee Clinical Research, a privately held contract research organization that conducts pharmaceutical development studies for commercial sponsors. ETCR’s major emphasis has been clinical studies with equines; however, safety, efficacy, pharmacokinetic and bioequivalence studies are also conducted with canines, felines, bovines and other domestic livestock at ETCR. Dr. Reinemeyer has authored over 70 peer-reviewed articles and book chapters, and has delivered over 200 papers at scientific meetings and continuing education conferences.

<< Back to top

Laurent L. Couetil, Ph.D.

Dr. Couetil currently serves as the Director of Equine Research Programs, the Director of Equine Sports Medicine Center, and Chief of Large Animal Medicine in the Department of Veterinary Clinical Sciences at the School of Veterinary Medicine, Purdue University. For the past 15 years, Dr. Couetil’s professional focus has been on identifying and treating diseases effecting sport equines.

Mary Robinson, VMD, Ph.D.

Dr. Mary Robinson is currently completing her fellowship from the Racing Medication and Testing Consortium at the University of Pennsylvania’s New Bolton Center under the guidance of Dr. Lawrence Soma. The focus of her research is on the detection of illegal extracorporeal shock wave therapy usage in the racehorse.

<< Back to top

John Byrd, Ph.D.

As President of Southwest Bio-Labs, Inc. in Las Cruces, NM, John runs one of the leading contract testing laboratories in the United States. Southwest Bio-Labs has conducted studies on behalf of most major animal health companies, and was the testing facility of choice for some of the industry’s most successful products, including Fort Dodge’s Quest Plus Gel and Bayer’s Marquis Antiprotozoal Oral Paste.

Linda Gebhard – LG Consulting Services

LG Consulting Services provides research quality assurance contract auditing, study monitoring, and consulting services for NewMarket. Ms. Gebhard has over 20 years of experience in Good Laboratory Practice and VICH regulated industry. She has facilitated FDA inspections and provided QA oversight to a variety of study types including toxicology, efficacy, target animal safety, reproductive safety, residue, bioequivalence and bioavailability, environmental assessment and stability studies, in addition to reviewing batch records for GMP materials. Her experience includes years of working in the contract research organization environment, as well as working for pharmaceutical companies and as a quality assurance consultant and contract monitor.

<< Back to top